title: Early Complete Molecular Response to First-Line Nilotinib in Two Patients with Chronic Myeloid Leukemia Carrying the p230 Transcript.
abstract: Chronic myeloid leukemia (CML) with the rare fusion gene e19a2, encoding a p230 protein, has been described in patients with typical or rather aggressive clinical course. Although tyrosine kinase inhibitors (TKIs) induce a substantial cytogenetic and molecular response in all phases of CML, a minority of p230 positive patients have been treated with TKIs. We report two cases of CML patients carrying the p230 transcript, who achieved fast and deep complete molecular response (CMR) after frontline treatment with nilotinib. Our results suggest the use of nilotinib as frontline agent for the treatment of this CML variant.
authors: Hematology Unit and Bone Marrow Transplantation Center, "R. Binaghi" Hospital, Via Is Guadazzonis 3, 09126 Cagliari, Italy.
authors: Marianna
authors: M
authors: Greco
authors: Giovanni
authors: G
authors: Caocci
authors: Giorgio
authors: G
authors: La Nasa
references: Exp Hematol. 2013 May;41(5):424-31
references: 23380384
references: Blood. 1990 Nov 1;76(9):1819-24
references: 2224129
references: J Clin Pathol. 2006 Oct;59(10):1102-3
references: 17021137
references: Case Rep Hematol. 2012;2012:458716
references: 22937329
references: Leuk Res. 2011 Sep;35(9):e169-70
references: 21641037
references: Cancer Genet Cytogenet. 2007 Jul 15;176(2):166-8
references: 17656262
references: Br J Haematol. 2002 Jul;118(1):251-4
references: 12100156
references: Blood. 1996 Oct 1;88(7):2410-4
references: 8839830
references: Oncogene. 2002 Dec 9;21(56):8652-67
references: 12476311
references: Leuk Res. 2010 Sep;34(9):e240-2
references: 20447687